<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01302873</url>
  </required_header>
  <id_info>
    <org_study_id>CBGG492A2210</org_study_id>
    <secondary_id>2010-022166-27</secondary_id>
    <nct_id>NCT01302873</nct_id>
  </id_info>
  <brief_title>Study of BGG492 in Patients With Chronic Subjective Tinnitus</brief_title>
  <official_title>A Multicenter, Randomized, Double-blind, Placebo- Controlled, Cross-over, Proof of Concept Study Comparing the Effects of Both Single Dose and Repeated Dosing Treatment for 2 Weeks of BGG492 in Patients With Chronic Subjective Tinnitus</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      This study will assess the efficacy of a two week treatment with BGG492 in patients with&#xD;
      chronic subjective Tinnitus.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2011</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">January 2012</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in tinnitus loudness using a visual analogue scale (VAS)</measure>
    <time_frame>after 15 days of treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Clinical status of tinnitus (patients' reaction to tinnitus) using the TBF-12 (Tinnitus Impairment Questionnaire)</measure>
    <time_frame>after 15 days of treatment</time_frame>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">96</enrollment>
  <condition>Chronic Subjective Tinnitus</condition>
  <arm_group>
    <arm_group_label>BGG492</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGG492A</intervention_name>
    <arm_group_label>BGG492</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BGG492A</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with THI (Tinnitus Handicap Inventory) severity grade 3, 4 or 5&#xD;
             (moderate, severe or catastrophic), chronic (&gt; 6 months and &lt; 36 months) subjective&#xD;
             tinnitus&#xD;
&#xD;
          -  Willing to abstain from activities that require focused attention, e.g. driving a car&#xD;
             or other vehicles, operating machines or engaging in potentially dangerous activities&#xD;
             that require focused attention and intact physical balance&#xD;
&#xD;
          -  Willing and able to refrain from engaging in activities or work involving loud noise&#xD;
             exposure&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients diagnosed with tinnitus of THI severity grade equal to 2 or 1&#xD;
&#xD;
          -  Patients with diagnosis of intermittent or pulsatile tinnitus&#xD;
&#xD;
          -  Patients who have tinnitus as a concomitant symptom of a treatable otological disease&#xD;
             (such as otitis media, Meni√®re's disease, otosclerosis), neurological tumors or/and&#xD;
             have temporo-mandibular joint disorders&#xD;
&#xD;
          -  Patients with a history of frequent middle ear infections (&gt; 3 infections per year&#xD;
             during the last 3 years)&#xD;
&#xD;
          -  Patients with diagnosed anxiety disorders, depression, schizophrenia or other&#xD;
             significant psychiatric diseases requiring current drug treatment or patients who&#xD;
             required treatment in the previous 3 months for these diseases.&#xD;
&#xD;
          -  Patients with current unilateral or bilateral hearing loss of 75 dB or more in one or&#xD;
             more tested frequencies (125 Hz, 250 Hz, 1 kHz, 2 kHz, 4 kHz, 6 kHz, 8 kHz)&#xD;
&#xD;
          -  Patients with Vestibular Schwannoma&#xD;
&#xD;
          -  Patients with a cochlear implant&#xD;
&#xD;
          -  Patients with regular intake of central nervous system acting drugs for the treatment&#xD;
             of tinnitus in the previous 6 months prior to initial dosing&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria may apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Berlin</city>
        <zip>10117</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Frankfurt</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Lepzig</city>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Groningen</city>
        <zip>9700</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <removed_countries>
    <country>Switzerland</country>
  </removed_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>February 7, 2011</study_first_submitted>
  <study_first_submitted_qc>February 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 24, 2011</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Tinnitus</keyword>
  <keyword>AMPA Receptor antagonist</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tinnitus</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

